337 related articles for article (PubMed ID: 25456402)
1. Decoding the function of the N-terminal tail of the cellular prion protein to inspire novel therapeutic avenues for neurodegenerative diseases.
Iraci N; Stincardini C; Barreca ML; Biasini E
Virus Res; 2015 Sep; 207():62-8. PubMed ID: 25456402
[TBL] [Abstract][Full Text] [Related]
2. High molecular mass assemblies of amyloid-β oligomers bind prion protein in patients with Alzheimer's disease.
Dohler F; Sepulveda-Falla D; Krasemann S; Altmeppen H; Schlüter H; Hildebrand D; Zerr I; Matschke J; Glatzel M
Brain; 2014 Mar; 137(Pt 3):873-86. PubMed ID: 24519981
[TBL] [Abstract][Full Text] [Related]
3. Influence of amino acid substitutions related to inherited human prion diseases on the thermodynamic stability of the cellular prion protein.
Liemann S; Glockshuber R
Biochemistry; 1999 Mar; 38(11):3258-67. PubMed ID: 10079068
[TBL] [Abstract][Full Text] [Related]
4. The cellular prion protein mediates neurotoxic signalling of β-sheet-rich conformers independent of prion replication.
Resenberger UK; Harmeier A; Woerner AC; Goodman JL; Müller V; Krishnan R; Vabulas RM; Kretzschmar HA; Lindquist S; Hartl FU; Multhaup G; Winklhofer KF; Tatzelt J
EMBO J; 2011 May; 30(10):2057-70. PubMed ID: 21441896
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity and Architecture of Pathological Prion Protein Assemblies: Time to Revisit the Molecular Basis of the Prion Replication Process?
Igel-Egalon A; Bohl J; Moudjou M; Herzog L; Reine F; Rezaei H; Béringue V
Viruses; 2019 May; 11(5):. PubMed ID: 31083283
[TBL] [Abstract][Full Text] [Related]
6. Exosomal cellular prion protein drives fibrillization of amyloid beta and counteracts amyloid beta-mediated neurotoxicity.
Falker C; Hartmann A; Guett I; Dohler F; Altmeppen H; Betzel C; Schubert R; Thurm D; Wegwitz F; Joshi P; Verderio C; Krasemann S; Glatzel M
J Neurochem; 2016 Apr; 137(1):88-100. PubMed ID: 26710111
[TBL] [Abstract][Full Text] [Related]
7. Roles of endoproteolytic α-cleavage and shedding of the prion protein in neurodegeneration.
Altmeppen HC; Prox J; Puig B; Dohler F; Falker C; Krasemann S; Glatzel M
FEBS J; 2013 Sep; 280(18):4338-47. PubMed ID: 23413979
[TBL] [Abstract][Full Text] [Related]
8. Molecular Mechanism of the Misfolding and Oligomerization of the Prion Protein: Current Understanding and Its Implications.
Singh J; Udgaonkar JB
Biochemistry; 2015 Jul; 54(29):4431-42. PubMed ID: 26171558
[TBL] [Abstract][Full Text] [Related]
9. Prion protein self-interactions: a gateway to novel therapeutic strategies?
Rigter A; Langeveld JP; van Zijderveld FG; Bossers A
Vaccine; 2010 Nov; 28(49):7810-23. PubMed ID: 20932496
[TBL] [Abstract][Full Text] [Related]
10. The function of the cellular prion protein in health and disease.
Watts JC; Bourkas MEC; Arshad H
Acta Neuropathol; 2018 Feb; 135(2):159-178. PubMed ID: 29151170
[TBL] [Abstract][Full Text] [Related]
11. The cell biology of prion-like spread of protein aggregates: mechanisms and implication in neurodegeneration.
Costanzo M; Zurzolo C
Biochem J; 2013 May; 452(1):1-17. PubMed ID: 23614720
[TBL] [Abstract][Full Text] [Related]
12. Prion channel proteins and their role in vacuolation and neurodegenerative diseases.
Kourie JI
Eur Biophys J; 2002 Sep; 31(5):409-16. PubMed ID: 12202918
[TBL] [Abstract][Full Text] [Related]
13. Prion proteins: a biological role beyond prion diseases.
Hu W; Rosenberg RN; Stüve O
Acta Neurol Scand; 2007 Aug; 116(2):75-82. PubMed ID: 17661791
[TBL] [Abstract][Full Text] [Related]
14. Cellular prion protein targets amyloid-β fibril ends via its C-terminal domain to prevent elongation.
Bove-Fenderson E; Urano R; Straub JE; Harris DA
J Biol Chem; 2017 Oct; 292(41):16858-16871. PubMed ID: 28842494
[TBL] [Abstract][Full Text] [Related]
15. Common therapeutic strategies for prion and Alzheimer's diseases.
Elezgarai SR; Biasini E
Biol Chem; 2016 Nov; 397(11):1115-1124. PubMed ID: 27279060
[TBL] [Abstract][Full Text] [Related]
16. Aggregation and amyloid fibril formation induced by chemical dimerization of recombinant prion protein in physiological-like conditions.
Roostaee A; Côté S; Roucou X
J Biol Chem; 2009 Nov; 284(45):30907-16. PubMed ID: 19710507
[TBL] [Abstract][Full Text] [Related]
17. Synthetic prions and other human neurodegenerative proteinopathies.
Le NT; Narkiewicz J; Aulić S; Salzano G; Tran HT; Scaini D; Moda F; Giachin G; Legname G
Virus Res; 2015 Sep; 207():25-37. PubMed ID: 25449570
[TBL] [Abstract][Full Text] [Related]
18. Neurometals in the Pathogenesis of Prion Diseases.
Kawahara M; Kato-Negishi M; Tanaka KI
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33525334
[TBL] [Abstract][Full Text] [Related]
19. PrP N-terminal domain triggers PrP(Sc)-like aggregation of Dpl.
Erlich P; Cesbron JY; Lemaire-Vieille C; Curt A; Andrieu JP; Schoehn G; Jamin M; Gagnon J
Biochem Biophys Res Commun; 2008 Jan; 365(3):478-83. PubMed ID: 17997980
[TBL] [Abstract][Full Text] [Related]
20. Aβ induces its own prion protein N-terminal fragment (PrPN1)-mediated neutralization in amorphous aggregates.
Béland M; Bédard M; Tremblay G; Lavigne P; Roucou X
Neurobiol Aging; 2014 Jul; 35(7):1537-48. PubMed ID: 24602510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
